



INVITROGEN CREATES UNIQUE SYSTEMS BIOLOGY CONCEPT THROUGH INTRODUCTION OF I-PATH

*225 original maps identifying and visualizing biologic pathways, available free to
researchers*

Carlsbad, CA. and Philadelphia, PA., June 20, 2005 – Invitrogen Corporation (NASDAQ - IVGN), a leading life sciences company with a broad portfolio of technologies to improve and accelerate biomedical research, drug discovery and commercial bioproduction, unveiled its latest concept in bioinformatics and systems biology with the launch of i-Path at the BIO 2005 international conference.

A new resource for scientists worldwide, i-Path consists of 225 high-level, annotated, validated original maps of human cell signaling and metabolic pathways compiled by GeneGo Inc, a leading provider of databases and software for systems biology. Invitrogen scientists have further identified the specific antibodies, siRNA, full-length DNA clones and other biological molecules involved in cell function and disease on these maps. The system enables researchers to visualize molecular interactions in a highly graphical, user-friendly, interactive format and will be available to scientists free of charge on Invitrogen's Web site.

"i-Path continues our tradition of providing enabling, Web-based technologies to support researchers throughout their experiments," said Michael Stapleton, Vice President & General Manager eCommerce and Bioinformatics for Invitrogen. "Building on a rich history that includes the acquisition of InforMax, Invitrogen has moved powerful design and analytic capabilities into the mainstream of science by coupling these systems with familiar research tools and making them freely available through our Web site."

i-Path includes maps of pathways that cover more than 2,500 genes—all of them human—of interest to biotech and pharmaceutical researchers. These include 171 signal transduction pathways representing the majority of known proteins involved in these processes and 54 metabolic pathways representing a significant number of genes involved in drug metabolism. The maps were created and annotated by a team of more than 40 scientists using information from thousands of scientific papers and validated with the accuracy and authenticity of pathways based on the latest scientific consensus. i-Path will also provide a time-saving link to reagents, kits and other Invitrogen research products related to the study of each molecule detailed in the pathway maps.

“With Invitrogen’s deep portfolio of research capabilities we are in a unique position to support systems biology as a driver of life science research and drug discovery,” said Gregory T. Lucier, Chairman and CEO of Invitrogen Corporation. “With our latest offerings we are solidifying our Website as the center of scientific conversation about the nature, structure and utility of biologic pathways.”

Details about Invitrogen’s new bioinformatics initiative will be made available at a news conference at the BIO 2005 conference, 2pm, Monday, June 20th in room 203B Demonstrations will also be available the Invitrogen booth in the exhibit hall. i-Path will be accessible at www.invitrogen.com/ipath beginning June 20, 2005.

About Invitrogen

Invitrogen Corporation (Nasdaq:IVGN) provides products and services that support academic and government research institutions and pharmaceutical and biotech companies worldwide in their efforts to improve the human condition. The company provides essential life science technologies for disease research, drug discovery and commercial bio-production. Invitrogen's own research and development efforts are focused on breakthrough innovation in all major areas of biological discovery, including functional genomics, proteomics, bio-informatics and cell biology, placing Invitrogen's products in nearly every major laboratory in the world. Founded in 1987, Invitrogen is headquartered in Carlsbad, Calif., and conducts business in more than 70 countries around the world. The company globally employs approximately 4,500 scientists and other professionals, and had revenues in excess of \$1 billion in 2004. Information about Invitrogen is available on the Web at www.invitrogen.com.

Forward-Looking Statements

Certain statements contained in this press release are considered "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, and it is Invitrogen’s intent that such statements be protected by the safe harbor created thereby. Forward-looking statements include, but are not limited to: 1) Invitrogen’s intent to provide i-Path content free of charge on its Web site; 2) Researchers’ ability to visualize their pathway of interest; 3) Invitrogen’s intent to link its technology portfolio to molecules identified in i-Path’s maps; 4) Invitrogen’s Web site becoming the center of scientific conversation around the nature, structure and utility of biologic pathways. Potential risks and uncertainties include, but are not limited to, the risks: a) Changing market conditions and restrictions on providing scientific content b) Availability and range of pathway content; c) Access to matching Invitrogen products from its catalog; d) Industry adoption and use of i-Path and Invitrogen’s Web site, as well as other risks and uncertainties detailed from time to time in Invitrogen's Securities and Exchange Commission filings.

Contacts:

Invitrogen Corporation:

Media - Greg Geissman (760) 476-7032, gregory.geissman@invitrogen.com

Investors - Adam Taich (760) 603-7267, adam.taich@invitrogen.com

BioCom Partners (Agency):

Stephen Gendel (212) 918-4650, sgendel@biocompartners.com

mobile (917) 856-3915